Clinical Trials
36 trialsNCT02364713 2025-12-11
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
Mayo Clinic
Phase 2 Terminated
NCT02569957 2025-05-04
Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Thomas Jefferson University
Phase 2 Terminated
NCT03891576 2025-01-17
Newton
Mario Negri Institute for Pharmacological Research
Phase 2 Terminated
NCT02923739 2024-03-13
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02834975 2023-11-07
Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).
University of Miami
Phase 2 Terminated
NCT04171700 2023-10-02
LODESTAR
pharmaand GmbH
Phase 2 Terminated
NCT02059265 2023-08-01
Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT03824704 2023-06-12
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
pharmaand GmbH
Phase 2 Terminated
NCT00373217 2022-09-21
Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
University of Virginia
Phase 2 Terminated
NCT03029611 2022-01-14
IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery
University of Washington
Phase 2 Terminated
NCT00582205 2021-05-19
Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
University of Oklahoma
Phase 2 Terminated
NCT03312114 2020-11-12
Anti-PD-L1 and SAbR for Ovarian Cancer
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT00322881 2018-09-10
Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT00866723 2018-05-22
Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT01773889 2018-04-10
A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Terminated
NCT00408070 2018-03-08
Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer
UConn Health
Phase 2 Terminated
NCT01936974 2018-02-20
PGA
Western Regional Medical Center
Phase 2 Terminated
NCT00574951 2018-01-11
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Terminated
NCT00331422 2017-12-28
Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00652899 2017-12-28
Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT02278783 2017-10-06
Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer
University of Utah
Phase 2 Terminated
NCT00354601 2017-08-30
Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer
Wake Forest University Health Sciences
Phase 2 Terminated
NCT01972516 2017-06-05
Tivozanib As Maintenance Therapy In GYN
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT01681368 2017-05-30
Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01659554 2017-03-10
HIPEC
Columbia University
Phase 2 Terminated
NCT01137071 2017-02-23
Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Recepta Biopharma
Phase 2 Terminated
NCT00522301 2016-02-29
Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT01296035 2015-08-25
PanGem
Women and Infants Hospital of Rhode Island
Phase 2 Terminated
NCT01200797 2015-05-25
SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00418093 2014-06-19
Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT00053833 2013-11-08
S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
SWOG Cancer Research Network
Phase 2 Terminated
NCT00748527 2013-07-10
Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00003624 2013-04-11
Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer
GOG Foundation
Phase 2 Terminated
NCT00445549 2012-06-26
Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00653328 2012-05-23
Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT00505661 2012-04-18
Letrozole in Patients With Ovarian Tumors
M.D. Anderson Cancer Center
Phase 2 Terminated